信立泰(002294.SZ)：SAL0137获得临床试验批准通知书

Core Viewpoint - The company, Xinlitai (002294.SZ), has received approval from the National Medical Products Administration for clinical trials of its innovative small molecule drug SAL0137, aimed at treating elevated lipoprotein (a) levels, which could provide new treatment options for patients and enhance the company's product pipeline in chronic disease management [1] Group 1 - The approval allows the company to conduct clinical trials for SAL0137, which is designed to address unmet clinical needs in treating elevated lipoprotein (a) levels [1] - Elevated lipoprotein (a) is an independent risk factor for various cardiovascular diseases, including coronary heart disease and ischemic stroke, increasing the risk through multiple mechanisms [1] - Preclinical studies indicate that SAL0137 has potential in treating elevated lipoprotein (a), suggesting significant development prospects [1]